Section Arrow
Quote
UNCY.NASDAQ
- Unicycive Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/21 06:41 EDT
Pre Market
Last
 4.53
+0.1 (+2.26%)
Bid
4.4
Ask
4.6
High 4.59 
Low 4.5 
Volume 133 
Regular Hours
Last
 4.43
-0.22 (-4.73%)
Day High 
4.67 
Prev. Close
4.65 
1-M High
8.2457 
Volume 
519.35K 
Bid
4.4
Ask
4.6
Day Low
4.42 
Open
4.64 
1-M Low
4.31 
Market Cap 
59.37M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.86 
20-SMA 5.45 
50-SMA 6 
52-W High 11 
52-W Low 2.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/8.75
Enterprise Value
59.49M
Balance Sheet
Book Value Per Share
0.88
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.15 -0.925 -6.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.21 +0.37 +6.34%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent beingdeveloped for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.